DAFTARIAN, PIROUZ MOHAMMAD,SERAFINI, PAOLO,LEMMON, VANCE PAUL,LI, WEI,KAIFER, ANGEL,BLOMBERG, BONNIE BETH,PEREZ, VICTOR L.
申请号：
CA2756996
公开号：
CA2756996C
申请日:
2010.04.01
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Nanoparticle -based vaccines, compositions, kits and methods are used for theeffective delivery of one or moreantigens in vivo for vaccination and antibody (e.g., monoclonal antibody)production, and for the effective delivery of peptides,proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g.tumor cells). Antigens may be, for example, DNAthat results in expression of the gene of interest and induction of a robustand specific immune response to the expressed proteinin a subject (e.g., mammal). Antigens may also be immunogenic peptides orpolypeptides that are processed and presented. In oneembodiment, a nanoparticle -based method to deliver antigens in vivo asdescribed herein includes injection of a vaccine com-posedof a DNA encoding at least one antigen, or at least one antigenic peptide orpolypeptide conjugated to a charged dendrimer(e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helperepitope (e.g., PADRE). Negatively-charged plasmidsbind naturally to a positively-charged PADRE-dendrimer, while peptide orpolypeptide antigens can be chemically linked to thePADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The composi-tions,kits, vaccines and methods described herein have both prophylactic andtreatment applications, i.e., can be used as a pro-phylacticto prevent onset of a disease or condition in a subject, as well as to treat asubject having a disease or condition. A vac-cineas described herein can be used to mount an immune response against anyinfectious pathogen or cancer.
